Osteopontin expression correlates with nuclear factor-κB activation and apoptosis downregulation in clear cell renal cell carcinoma

Pathology Research and Practice

Volumn 207, Issue 2, 2011, Pages 104-110

  Matušan Ilijaš, Koviljka ^a   Damante, Giuseppe ^b   Fabbro, Dora ^c   Dordević, Gordana ^a   Hadžisejdić, Ita ^a   Grahovac, Maja ^d   Marić, Ivana ^a   Španjol, Josip ^e   Grahovac, Blaženka ^a   Jonjić, Nives ^a   Lučin, Ksenija ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b UNIVERSITY OF UDINE   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e KBC RIJEKA   (Croatia)

Author keywords

Apoptosis; Carcinoma; Nuclear factor kappa B; Osteopontin; Renal cell

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOPONTIN; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL PROTECTION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

APOPTOSIS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KIDNEY NEOPLASMS; OSTEOPONTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR RELA;

EID: 79551583112     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.11.004     Document Type: Article

References (42)

1. An J., Sun Y., Fisher M., Rettig M.B. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol. Cancer Ther. 2004, 3:727-736.
2. Brown L.F., Papadopoulos-Sergiou A., Berse B., Manseau E.J., Tognazzi K., Perruzzi C.A., Dvorak H.F., Senger D.R. Osteopontin expression and distribution in human carcinomas. Am. J. Pathol. 1994, 145:610-623.
3. Burdo T.H., Wood M.R., Fox H.S. Osteopontin prevents monocyte recirculation and apoptosis. J. Leukoc. Biol. 2007, 81:1504-1511.
4. Coppola D., Szabo M., Boulware D., Muraca P., Alsarraj M., Chambers A.F., Yeatman T.J. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 2004, 10:184-190.
5. Das R., Philip S., Mahabeleshwar G.H., Bulbule A., Kundu G.C. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 2005, 57:441-447.
6. Denhardt D.T., Mistretta D., Chambers A.F., Krishna S., Porter J.F., Raghuram S., Rittling S.R. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin. Exp. Metastasis 2003, 20:77-84.
7. Djordjević G., Matusan-Ilijas K., Sinozić E., Damante G., Fabbro D., Grahovac B., Lucin K., Jonjić N. Relationship between vascular endothelial growth factor and nuclear factor-kappaB in renal cell tumors. Croat. Med. J. 2008, 49:608-617. N.
8. Dolcet X., Llobet D., Pallares J., Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005, 446:475-482.
9. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. WHO Classification of Tumors Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs 2004, IARC Press, Lyon, 9-87.
10. Fedarko N.S., Fohr B., Robey P.G., Young M.F., Fisher L.W. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J. Biol. Chem. 2000, 275:16666-16672.
11. Fong Y.C., Liu S.C., Huang C.Y., Li T.M., Hsu S.F., Kao S.T., Tsai F.J., Chen W.C., Chen C.Y., Tang C.H. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2009, 64:263-270.
12. Gilmore T.D. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999, 18:6842-6844.
13. Godley P., Kim S.W. Renal cell carcinoma. Curr. Opin. Oncol. 2002, 14:280-285.
14. Hsieh Y.H., Juliana M.M., Hicks P.H., Feng G., Elmets C., Liaw L., Chang P.L. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res. 2006, 66:7119-7127.
15. Jain S., Chakraborty G., Kundu G.C. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res. 2006, 66:6638-6648.
16. Lin Y.H., Yang-Yen H.F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J. Biol. Chem. 2001, 276:46024-46030.
17. Lucin K., Matusan K., Dordevic G., Stipić D. Prognostic significance of CD44 molecule in renal cell carcinoma. Croat. Med. J. 2004, 45:703-708.
18. Maihöfner C., Charalambous M.P., Bhambra U., Lightfoot T., Geisslinger G., Gooderham N.J. Expression of cyclooxygenase-2 parallels expression sof interleukin-1beta interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis 2003, 24:665-671.
19. Matusan K., Dordevic G., Stipic D., Mozetic V., Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J. Surg. Oncol. 2006, 94:325-331.
20. Meteoglu I., Erdogdu I.H., Meydan N., Erkus M., Barutca S., NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J. Exp. Clin. Cancer Res. 2008, 27:53.
21. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5:297-309.
22. Nakayama H., Ikebe T., Beppu M., Shirasuna K. High expression levels of nuclear factor kappaB IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 2001, 92:3037-3044.
23. Oya M., Ohtsubo M., Takayanagi A., Tachibana M., Shimizu N., Murai M. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 2001, 20:3888-3896.
24. Oya M., Takayanagi A., Horiguchi A., Mizuno R., Ohtsubo M., Marumo K., Shimizu N., Murai M. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003, 24:377-384.
25. Philip S., Bulbule A., Kundu G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 2001, 276:44926-44935.
26. Qi H., Ohh M. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res. 2003, 63:7076-7080.
27. Rabb H., Barroso-Vicens E., Adams R., Pow-Sang J., Ramirez G. Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney. Am. J. Nephrol. 1996, 16:402-408.
28. Ramankulov A., Lein M., Kristiansen G., Meyer H.A., Loening S.A., Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J. Cancer Res. Clin. Oncol. 2007, 133:643-652. K.
29. Rangaswami H., Bulbule A., Kundu G.C. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. 2004, 279:38921-38935.
30. Renault M.A., Jalvy S., Potier M., Belloc I., Genot E., Dekker L.V., Desgranges C., Gadeau A.P. UTP induces osteopontin expression through a coordinate action of NFkappaB activator protein-1, and upstream stimulatory factor in arterial smooth muscle cells. J. Biol. Chem. 2005, 280:2708-2713.
31. Ross J.S., Kallakury B.V., Sheehan C.E., Fisher H.A., Kaufman R.P., Kaur P., Gray K., Stringer B. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin. Cancer Res. 2004, 10:2466-2472.
32. Samant R.S., Clark D.W., Fillmore R.A., Cicek M., Metge B.J., Chandramouli K.H., Chambers A.F., Casey G., Welch D.R., Shevde L.A. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol. Cancer 2007, 6:6.
33. Sasaki N., Morisaki T., Hashizume K., Yao T., Tsuneyoshi M., Noshiro H., Nakamura K., Yamanaka T., Uchiyama A., Tanaka M., Katano M. Clin. Cancer Res. 2001, 7:4136-4142.
34. Scatena M., Almeida M., Chaisson M.L., Fausto N., Nicosia R.F., Giachelli C.M. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J. Cell Biol. 1998, 141:1083-1093.
35. Shukla S., MacLennan G.T., Fu P., Patel J., Marengo S.R., Resnick M.I., Gupta S. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004, 6:390-400.
36. Sourbier C., Danilin S., Lindner V., Steger J., Rothhut S., Meyer N., Jacqmin D., Helwig J.J., Lang H., Massfelder T. Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res. 2007, 67:11668-11676.
37. Standal T., Borset M., Sundan A. Role of osteopontin in adhesion migration cell survival and bone remodeling. Exp. Oncol. 2004, 26:179-184.
38. Vousden K.H. Partners in death: a role for p73 and NF-(B in promoting apoptosis. AGING 2009, 1:275-277.
39. Wai P.Y., Kuo P.C. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008, 27:103-118.
40. Xie Y., Sakatsume M., Nishi S., Narita I., Arakawa M., Gejyo F. Expression roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 2001, 60:1645-1657.
41. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., Chiao P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 1999, 5:119-127.
42. Zhao J., Dong L., Lu B., Wu G., Xu D., Chen J., Li K., Tong X., Dai J., Yao S., Wu M., Guo Y. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008, 135:956-968.